Results 111 to 120 of about 28,849 (195)

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology. [PDF]

Ann Hematol
Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S, Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, Botta C, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F.   +43 more
europepmc   +1 more source

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc</i> expert panel. [PDF]

Haematologica, 2022
De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, Offidani M, Petrucci MT, Ruggeri M, Santi RM, Barosi G.   +10 more
europepmc   +1 more source

JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib. [PDF]

Br J Haematol
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, Ceresa D, Colombo M, Vigo T, Cigolini B, Rivoli G, Dragani M, Solimano I, Garuti A, Bellodi A, Ballestrero A, Ferrando L, Zoppoli G.   +17 more
europepmc   +1 more source

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. [PDF]

Front Oncol, 2022
Bonello F, Rocchi S, Barilà G, Sandrone M, Talarico M, Zamagni E, Scaldaferri M, Vedovato S, Bertiond C, Pavan L, Bringhen S, Cattel F, Zambello R, Cavo M, Mina R.   +14 more
europepmc   +1 more source

Abordagem do Mieloma Múltiplo em Doentes Jovens - A propósito de um caso clínico [PDF]

, 2014
Inês Filipa Monteiro Cordeiro Ferro
core  

Correction: Colomba et al. Haemodynamic Forces: Emerging Markers of Ventricular Remodelling in Multiple Myeloma Cardiovascular Baseline Risk Assessment. Cancers 2024, 16, 3081. [PDF]

Cancers (Basel)
Colomba A, Astarita A, Mingrone G, Airale L, Catarinella C, Vallelonga F, Leone D, Cesareo M, Paladino A, Bringhen S, Gay F, Pedrizzetti G, Veglio F, Milan A.   +13 more
europepmc   +1 more source

New Strategies for the Treatment of Older Myeloma Patients. [PDF]

Cancers (Basel), 2023
Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S.   +4 more
europepmc   +1 more source

8º Annual Meeting of the Italo-Brazilian Hematology Association [PDF]

, 2009
RUIZ, Milton A.
core   +2 more sources

Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research. [PDF]

JACC CardioOncol
Cagnazzo R, Stabile M, Zoppoli G, De Boer RA, Meijers WC, van Der Meer P, Ameri P.   +6 more
europepmc   +1 more source

[Therapeutic alternatives for drug-associated maxillary osteonecrosis (MRONJ): reports of two clinical cases and review of the literature]. [PDF]

Rev Fac Cien Med Univ Nac Cordoba, 2022
Leonardi N, Gilligan G, Piemonte E, Panico R.   +3 more
europepmc   +1 more source